GlassScriptPhysician profile
Michael Tawfellos
NPI 1609874270
$2,210.67
in general payments reported to CMS, 2019-2025
22 companies · $448 in 2025
The $448 reported for 2025 was more than what 90% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $237 · 2021: $377 · 2022: $114 · 2023: $428 · 2024: $392 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $709.87 | 2020-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $342.11 | 2022-2025 | Stelara, Tremfya |
| Ardelyx, INC. | $190.33 | 2023-2025 | Ibsrela |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.87 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $92.31 | 2020-2024 | Ocaliva |
| Abbvie INC. | $87.17 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $85.97 | 2019-2024 | Dificid |
| Redhill Biopharma INC. | $68.21 | 2020-2022 | |
| Shionogi INC | $62.35 | 2019 | |
| Phathom Pharmaceuticals, INC. | $53.87 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $48.00 | 2021 | |
| Braintree Laboratories, INC. | $45.37 | 2020-2024 | Suflave |
| Lilly USA, LLC | $39.29 | 2023-2025 | Omvoh |
| Concordia Pharmaceuticals INC. | $38.20 | 2019 | |
| Alfasigma USA, INC. | $31.65 | 2020-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $29.78 | 2021-2022 | |
| Endo Pharmaceuticals INC. | $25.42 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $23.73 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $21.06 | 2024 | |
| Fresenius Kabi USA, LLC | $18.06 | 2023 | |
| Boston Scientific Corporation | $15.83 | 2019 | |
| Evoke Pharma, INC. | $14.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Tawfellos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.